A Heart Health check for Maori and Pacific People in Hospital

Not Applicable

• Conditions: Cardiovascular disease; Cardiovascular - Coronary heart disease; Stroke - Ischaemic; Public Health - Health service research

• Registration Number: ACTRN12624000920594
• Lead Sponsor: Christchurch Hospital Pharmacy Department

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-30
• Last Update Posted: 12 August 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

oMaori or Pacific Male* aged 30 or above
oMaori or Pacific Female* aged 40 or above
oLive in greater Christchurch area to ensure appropriate community follow up can be arranged.

(*Sex at birth)

Exclusion Criteria

High risk CVD features that automatically define risk as > 15%
oHeart failure
oCoronary or carotid artery disease from imaging (unlikely to have in community)
oeGFR < 30 mL/min or < 45mL/min with diabetes
oPrevious Cardiovascular event
oFamilial hypercholesterolaemia

oAge greater than 75 (as the PREDICT CVD RA tool is only validated for < 75 years)
oPregnant / Breastfeeding
oNot appropriate due to clinical or emotional status (too unwell) or prognosis (short life expectancy)
Note: If deemed inappropriate due to current clinical status, this can be reassessed at a later date during their admission
oPatient had CVD RA completed previously + clearly recalls their risk level AND is not due to repeat assessment (see below) AND appears appropriately treated for risk level.
Note: Due to variance in completion rates / quality / timeliness and patient recall of previous CVD RA – better to assess again if any concerns to appropriately manage cardio-vascular disease risk.

Recommended interval for repeat CVD risk assessment
Risk < 3% – ten years
Risk 3–9% – five years
Risk 10–14% – two years
Risk = 15% – one year
Risk 5–15% and prescribed pharmacological interventions – one year
Severe mental illness – two years (or one year if risk greater than or equal to 15%)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of study participants who have CVD RA completed by pharmacist in hospital. [An electronic note will be added to the patient's clinical record outlining completion of CVD RA. This data will be pulled from electronic records Assessed 3 months after study implementation];To calculate the proportion of eligible Maori and Pacific people who have received a CVD RA before and after this intervention in Christchurch.[Data pulled from electronic clinical notes on specific pharmacy CVD RA form Comparison of Health NZ CVD RA completion rates and the data assessed 3 months after study implementation]

Secondary Outcome Measures

Name	Time	Method
umber of study participants on CVD preventative medications (statin) who have had these titrated if not meeting lipid targets.[Data pulled from electronic clinical notes on specific pharmacy CVD RA form Assessed 3 months after study implementation or when reached 200 participants enrolled.];Number participants with newly identified diabetes or pre-diabetes.[Data pulled from electronic clinical notes on specific pharmacy CVD RA form Assessed 3 months after study implementation or when reached 200 participants enrolled.];Proportion of study participants with Intermediate or High risk (or equivalent risk) of CVD agreeable to starting a statin at discharge[Data pulled from electronic clinical notes on specific pharmacy CVD RA form Assessed 3 months after study implementation or when reached 200 participants enrolled.]